Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-025 CAR-T in Advanced NKG2DL+ Solid Tumors
NCT05382377Phase 1Recruiting
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belumosudil in solid tumor. Primary endpoints: Treatment-Emergent Adverse Events at 3 months, Dose-Limiting Toxicity Rate at 3 months and 1 more. Started May 2022; status: recruiting.
02
Drugs
belumosudil
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05382377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382377.